Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose monohydrate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; povidone; crospovidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (eg. diuretics, digoxin, ace inhibitors and vasodilators).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (eg. diuretics, digoxin, ace inhibitors and vasodilators).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - dicarz is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dicarz is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (eg. diuretics, digoxin, ace inhibitors and vasodilators).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 200 mg - tablet, uncoated - excipient ingredients: calcium carbonate; mannitol; hyprolose; fumaric acid; iron oxide yellow; magnesium stearate - treatment of erectile dysfunction in adult males.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; calcium carbonate; fumaric acid; mannitol; hyprolose - treatment of erectile dysfunction in adult males.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - avanafil, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; fumaric acid; calcium carbonate; hyprolose; iron oxide yellow - treatment of erectile dysfunction in adult males.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 35.125 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; magnesium stearate; calcium hydrogen phosphate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 25 mg tablets is not indicated for use by women.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 140.5 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: hypromellose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 100 mg tablets is not indicated for use by women.